Immutep (IMM.AX) Stock Price
Immutep Price
Over the last 19 years Immutep grew revenue by 102.0% annually, reaching 14.56 M AUD. For Immutep, the net margin of -544.8% is up versus -18,906.5% a few years ago.
Immutep stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Immutep business model & stock analysis
Frequently asked questions about Immutep
The business model of Immutep Ltd revolves around developing and commercializing immunotherapy treatments. Immutep Ltd focuses on the development of LAG-3 related products, which play a crucial role in regulating the immune system. By leveraging its expertise and technology, the company aims to treat a wide range of diseases, including cancer and autoimmune disorders. Immutep Ltd collaborates with various partners and conducts clinical trials to evaluate the safety and effectiveness of its therapies. Through strategic partnerships and licensing agreements, the company aims to bring its innovative treatments to market, ultimately improving patient outcomes and advancing the field of immunotherapy.
Immutep Ltd is primarily active in the biotechnology and healthcare industries.
The main competitors of Immutep Ltd in the market include companies like Bristol-Myers Squibb, AstraZeneca, Merck, Roche, and Novartis. These companies also operate in the biopharmaceutical sector and focus on developing innovative treatments and therapies. Immutep Ltd differentiates itself through its unique therapeutic pipeline and commitment to the development of immunotherapies. With their focus on immunomodulation and immuno-oncology, Immutep Ltd aims to make a significant impact in the field of cancer treatment and autoimmune diseases, setting itself apart from its competitors.
Immutep Ltd is an Australian biotechnology company specializing in developing immunotherapy treatments for cancer and autoimmune diseases. Established in 2001, Immutep has a rich history of pioneering research and significant advancements in the field of immune-based therapies. The company's extensive expertise lies in the development of its lead product candidate, eftilagimod alpha (efti), a soluble LAG-3 protein aimed at enhancing immune responses. Immutep Ltd has collaborated with renowned pharmaceutical companies and research institutions worldwide, reinforcing its dedication to advancing immunotherapy and ultimately improving patient outcomes. With a strong focus on innovation, Immutep continues to make significant contributions in the immunotherapy space, propelling the fight against cancer and autoimmune diseases forward.
Immutep Ltd, a leading biotechnology company, has achieved several significant milestones. Firstly, the company successfully completed a Phase IIb clinical trial for its flagship product, Eftilagimod Alpha (efti). The trial demonstrated promising results in treating metastatic breast cancer. Secondly, Immutep entered into a strategic collaboration with major pharmaceutical companies to further develop and commercialize efti. This collaboration enhances its growth potential and market reach. Additionally, Immutep received Fast Track designation from the U.S. FDA for efti, expediting its regulatory process. These accomplishments showcase Immutep Ltd's dedication to advancing breakthrough immunotherapies and solidify its position in the biotech industry.
Immutep Ltd is primarily present in several countries and regions worldwide. These include Australia, where the company is headquartered, as well as the United States, Europe, and Asia-Pacific. With a focus on developing novel immunotherapy treatments, Immutep Ltd has established a global presence to reach patients and collaborate with healthcare and bio-pharmaceutical partners across these regions.
Immutep Ltd is a leading biotechnology company that focuses on developing novel immunotherapeutic treatments. The company is dedicated to improving the lives of patients with cancer and autoimmune diseases through innovative research and development. Immutep's core values revolve around scientific excellence, integrity, and patient-centricity. With a commitment to advancing cutting-edge therapies, Immutep embraces a corporate philosophy centered on collaboration, innovation, and delivering breakthrough solutions. By harnessing the power of the immune system, Immutep aims to revolutionize the way diseases are treated, offering hope and improved outcomes to patients worldwide.
10 analysts currently rate the Immutep stock: 9 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Immutep share trades at 0.01 EUR (0.02 AUD).
The Immutep share (IMM.AX) is listed on 4 stock exchanges, including: ASX (IMM.AX), Frankfurt (YP1B.F), München (YP1B.MU).
Immutep Ltd is an Australian biotechnology company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. The company has two main product platforms, the Lymphocyte Activation Gene (LAG)-3 platform and the IMP321 platform. Its leading products are IMP321, an agonistic LAG-3 antibody, and eftilagimod alpha, an IMP321-based immunotherapy. Immutep also offers services for preclinical and clinical development of immunotherapies. The company has partnerships with pharmaceutical companies such as Novartis, GlaxoSmithKline, and Eddingpharm. It has a portfolio of patents and intellectual property in the LAG-3 and IMP321 areas, and has licensed its LAG-3 technology for predictive diagnostics in cancer patients. Overall, Immutep aims to research, develop, and market immunotherapies for the treatment of cancer and autoimmune diseases, as well as provide services for their development. It positions itself as a leading provider of immunotherapies based on LAG-3 and IMP321 technologies. Immutep Ltd is an Australian biotechnology company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. It has two main product platforms, LAG-3 and IMP321. Leading products include IMP321 and eftilagimod alpha. The company also offers services for preclinical and clinical development of immunotherapies. It has partnerships with Novartis, GlaxoSmithKline, and Eddingpharm. Immutep has patents and intellectual property in the LAG-3 and IMP321 areas. It has licensed its LAG-3 technology for predictive diagnostics in cancer patients. Overall, Immutep aims to research, develop, and market immunotherapies for cancer and autoimmune diseases, as well as provide development services. It positions itself as a leading provider of immunotherapies based on LAG-3 and IMP321 technologies.
The revenue of Immutep is 14.56 M AUD. This figure is based on current financial data and reflects the company's business performance.
The profit of Immutep is -79.30 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Immutep is currently -0.43. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Immutep stock.
The price-to-sales ratio (P/S) of Immutep is currently 2.33. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Immutep stock.
The Eulerpool Quality Score for Immutep is 4/10.
The ISIN of Immutep is AU000000IMM6. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Immutep is A2H81H. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Immutep is IMM.AX. The ticker symbol is used to trade Immutep shares on the stock exchange.
Immutep stock
Immutep Peer Group
Immutep Ticker
Immutep FIGI
All fundamentals and in-depth analysis of Immutep
Our stock analysis for Immutep stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immutep. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.